KPRX (Kiora Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Jul. 11, 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
34 GF Score
Price $2.52
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kiora Pharmaceuticals  (NAS:KPRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kiora Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Kiora Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KPRX vs PHIO, PBM, OSRH: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


KPRX
34GF Score
Kiora Pharmaceuticals Inc KPRX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kiora Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Kiora Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Kiora Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 117.500 241.018 160.984
201609 137.000 241.428 187.382
201612 80.000 241.432 109.418
201703 92.500 243.801 125.285
201706 74.000 244.955 99.756
201709 25.000 246.819 33.447
201712 0.000 246.524 0.000
201803 365.333 249.554 483.413
201806 34.571 251.989 45.303
201809 39.375 252.439 51.506
201812 0.000 251.233 0.000
201903 223.833 254.202 290.763
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 0.923 260.474 1.170
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 4.111 312.332 4.346
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for KPRX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.52
Price